2 results
Approved WMOCompleted
To compare prostate-specific antigen (PSA) progression-free survival (PFS) failure rates during long-term treatment with 3-monthly subcutaneous (s.c.) injections of degarelix or goserelin in prostate cancer patients (PSA PFS failure is defined as…
Approved WMOCompleted
To assess the PD, PK and safety of the Zoreline 10.8 mg goserelin subcutaneous (SC) implant.